Modelling and simulation of chemotherapy of haematological and gynaecological cancers

IMA Journal of Mathemathics Applied in Medicine and Biology

Volumn 16, Issue 1, 1999, Pages 39-91

  Nani, Frank K ^a   Oǧuztöreli, M Namik ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Chemotherapy; Functional differential equations; Haematological and gynaecological cancers; Mathematical modelling and simulations

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; COMPUTER SIMULATION; GYNECOLOGIC CANCER; LEUKEMIA; LYMPHOMA; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL;

CANCER CELLS; CELLS; CONTROLLED DRUG DELIVERY; CYTOLOGY; DIFFERENTIAL EQUATIONS; DISEASES; DRUG DOSAGE; INDIUM COMPOUNDS; TARGETED DRUG DELIVERY; TUMORS;

ANTINEOPLASTIC DRUGS; CELL CYCLE PHASE; DEGRADATION PARAMETER; DELIVERY ROUTES; FUNCTIONAL DIFFERENTIAL EQUATIONS; HEMATOLOGICAL AND GYNECOLOGICAL CANCER; MATHEMATICAL MODELING AND SIMULATION; MODEL AND SIMULATION; MODELING EQUATIONS; TUMOUR CELLS;

CHEMOTHERAPY;

EID: 0344178181     PISSN: 02650746     EISSN: None     Source Type: Journal    
DOI: 10.1093/imammb16.1.39     Document Type: Article

References (108)

1. AGUR, Z., ARNON, R. & SCHECHTER, B. 1992 Effects of dosing interval on myelotoxicity and survival in mice treated by Cytarabine. Eur. J. Cancer A 28, 1085-1090.
2. ANWAD, H. K. 1990. Radiation Oncology: Radio-Biological and Physiological Perspective, pp. 63-64, London: Kluwer, Academic Press.
3. ARINO, O. & KIMMEL, M. 1987 Asymptotic analysis of a cell cycle model based on unequal division. SIAM J. Appl. Math. 47, 128-145.
4. ARINO, O. & KIMMEL, M. 1989 Asymptotic behavior of a nonlinear functional integral equation of cell kinetics with unequal division. J. Math. Biol. 27, 341-354.
5. ARINO, O. & MORTABIT, A. 1991 Slow oscillations in a model of cell cycle population dynamics. Lecture Notes in Pure and Applied Mathematics Vol. 131, pp. 13-25. New York: Marcel Dekker.
6. BASERGA, R. 1971 Cell cycle of cancer cells in man. In: The Cell Cycle and Cancer Cells. The Biochemistry of Disease, Vol. 1 (R. Baserga, ed.), pp. 104-105. New York: Marcel Dekker.
7. 1 phase of the cell cycle. J. Cell Physiol. 95, 377-386.
8. BASERGA, R. 1985 The Biology of Cell Reproduction. Cambridge, MA: Harvard University Press.
9. BELLMAN, R. & COOKE, K. L. 1963 Differential-Difference Equations. New York: Academic Press.
10. BHUYAN, B. K. 1977 Cell cycle related cellular lethality. In: Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells (B. Drewinko & R. M. Humphrey, eds.), pp. 362-375.
11. 1 transit time relative to the Cycloheximide and Actinomycin-D drug restriction points. Cell Tissue Kinetics 14, 91-101.
12. BLESSING, J. A. 1990. Design, analysis and interpretation of chemotherapy: Trials in gynaecologic cancer. In: Chemotherapy of Gynecologic Cancer (G. Deppe, ed.), pp. 63-97. New York: Wiley-Liss.
13. BOS, J. L. 1988 The ras oncogene family and human carcinogenesis. Mut. Res. 195, 255-271.
14. BROOKS, R. F. 1981 Variability in Cell Cycle and the Control of Proliferation in the Cell Cycle, pp. 35-67. Cambridge University Press.
15. CALVIN, M. 1978 Review of the pharmacology and clinical use of cyclophosphamide. In: Clinical Pharmacology of Antineoplastic Drugs (H. M. Pinedo, ed.), pp. 245-261. Calvin: Elsevier/North-Holland Biomedical Press.
16. CLARKSON, B. 1974 Clinical applications of cell cycle kinetics. In: Handbuch der Experimentellen Pharmakologie XXXVIII/1 (A. C. Sartorelli & D. G. John, eds.), pp. 156-193. Berlin: Springer.
17. COJOCARU, L. & AGUR, Z. 1992 A theoretical analysis of interval drug dosing for cell-cycle-phase specific drug. Math. Biosci. 109, 85-97.
18. COPPER, S. 1991 Conjectures on the mathematics of cell cycle. In: Lecture Notes in Pure and Applied Mathematics Vol. 131, pp. 539-546. New York: Marcel Dekker.
19. DALLA-FAVERA, R. et al. 1987 Advances on the Molecular Pathogenesis of Burkitt Lymphoma: Recent Advances in Leukaemia and Lymphoma, pp. 165-177. New York: A.R. Liss.
20. DATKO, R. 1975 The uniform asymptotic stability of certain linear differential-difference equations. Proc. R. Soc. Edinburgh A 74, 71-79.
21. DONAGHEY, C. E. 1986 Cell kinetics simulation languages. Bull. Math. Biol. 48, 323-336.
22. DRIVER, R. D. 1977 Ordinary and Delay Differential Equations. New York: Springer-Verlag.
23. EISEN, M. 1979 Mathematical Models in Cell Biology and Cancer Chemotherapy. Lecture Notes in Biomathematics Vol. 40, pp. 122-218. New York: Springer-Verlag.
24. EISENFELD, J. 1979 Relationship between stochastic and deterministic models of compartmental systems. Math. Biosci. 43, 289-305.
25. EKSBORG, S. 1978 Extraction properties and HPLC separation of Adriamycin and Daunorubicin. Application to bioanalysis. In: Clinical Pharmacology of Antineoplastic Drugs (H.M. Pinedo, ed.), pp. 193-205. Oxford: Elsevier/North-Holland Biomedical Press.
26. EL'SGOL'TS, L. E. 1966 Introduction to the Theory of Differential Equations with Deviating Arguments. San Fransisco: Holden-Day.
27. EMMANUEL, N. M. & EVSEENKO, L. S. 1973 Clinical Oncology. A Quantitative Approach. Israel Program for Scientific Translations, London, pp. 14-15. New York: Wiley.
28. ERLICHMAN, C., SOLDIN, S. J., TIESSEM, J. J., STURGEON, J. F. G., & FINE, S. 1987 Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer. Cancer Chemother. Pharmacol. 19, 75-79.
29. FIELDING, R. M. 1991 Liposomal drug delivery, advantages and limitations: From a pharmacokinetic and therapeutic point of view. Clinical Pharmacokin. 21, 155-164.
30. FIETKAU, R., FRIDE, H., & MAURIER-SHULGE, B. 1984 Cell kinetic studies of the cytostatic and cytocidal effect of Ara-C on the L1210 ascites tumour. Cancer Res. 44, pp. 1105-1113.
31. FREI, E. III. 1985 Curative cancer chemotherapy. Cancer Res. 45, 6523-6548.
32. FREI, E. III. HEWLETT, J. N., BICKERS, J. S., LANE, M., LEARY, W. V., & TALLEY, R. W. 1969 Dose schedule and anti-tumour studies of Ara-C. Cancer Res. 29, 1325-1332.
33. GAMBKE, C., HALL, A., & MORONI, C. 1984 Activation of an N-ras gene in acute myleloblastic leukaemia. Proc. Natl. Acad. Sci. USA 82, 879-882.
34. GAVOSTO, F. & PILERA, A. 1971 Cell cycle of cancer cells in man. In: The Cell Cycle and Cancer (R. Baserga, e;d.), pp. 99-128. New York: Marcel Dekker.
35. GOLDIE, J. H. & COLDMAN, A. J. 1979 A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727-1733.
36. GOLDIE, J. H. & COLDMAN, A. J. 1983 Quantitative model for multiple levels of drug resistance in clinical tumours. Cancer Treat. Rep. 67, 923-931.
37. GOTTLIEB, G. & ACKERMAN, A. B. 1988 Kaposi's Sarcoma: A Text and Atlas, pp. 173-253. Philadelphia, PA: Lea & Febiger.
38. GYLLENBERG, M. & WEBB, G. F. 1987 Age-size structure in tumour populations with quiescence. Math. Biosci. 86, 67-95.
39. GYLLENBERG, M. & WEBB, G. F. 1989 Quiescence as an explanation of Gompertzian tumour growth. Growth, Develop. Aging 53, 25-33.
40. GYLLENBERG, M. & WEBB, G. F. 1991 Quiescence in Structured Population Dynamics: Applications to Tumour Growth. Lecture Notes in Pure and Applied Mathematics, Vol. 131, pp. 45-62.
41. HALANAY, A. 1965 Differential Equations. Stability, Oscillations, Time-Lags. New York: Academic Press.
42. HALE, J. 1977 Theory of Functional Differential Equations. New York: Springer-Verlag.
43. HAND, R. 1978 Eucaryotic DNA. Cell 15, 317-325.
44. HARNEVO, L. E. & AGUR, Z. 1993 Use of mathematical modeling for understanding the dynamics of gene amplification. Mutat. Res. 292, 17-24.
45. KAMENTSKY, L. A., MELAMED, H. R. & DERMAN, H. 1965 Spectrophotometer: New instrument for ultra-rapid cell analysis. Science 150, 630.
46. KATO, T. 1983 Encapsulated drugs in targeted cancer therapy. In: Controlled Drug Delivery II (S.D. Bruck, ed.). Boca Raton, FL: CRC Press.
47. KIM, M., WOO, K. B. & PERRY, S. 1977 Quantitative approach to the design of anti-tumour drug dosage schedule via cell cycle kinetics and systems theory. Ann. Biomed. Eng. 5, 12.
48. KIMMEL, M., KIMMEL, B. & SKIERSKI, J. 1993 Mathematical model of leukaemic cell circulation in mouse. Math. Biosci. 67, 81-99.
49. KLEIN, H. O. & LENNARTZ, K. J. 1974 Chemotherapy after synchronization of tumour cells. Semin. Hemat. 11, 203-227.
50. KNOLLE, H. 1988 Cell Kinetic Modeling and the Chemotherapy of Cancer. Lecture Notes in Biomathematics, Vol. 75, (S. Levin, ed.). New York: Springer-Verlag.
51. KOLMANOVSKII, V. B. & Nosov, V. R. 1986 Stability of Functional Differential Equations. London: Academic Press.
52. LANKELMA, J., KLEIJN, E. VAN DER, & TERMOND, F. S. 1978 Assay of Methotrexate by HPLC and its application to clinical pharmokinetics. In: Clinical Pharmacology of Antineoplastic Drugs (H. M. Pinedo, ed.), pp. 13-28. Oxford: Elsevier/North-Holland Biomedical Press.
53. LOKICH, J. J. (ed.) 1990. Cancer Chemotherapy by Infusion. Chicago: Precept Press.
54. MACDONALD, P. D. M. 1974 Stochastic Models for Cell Proliferation. Lecture Notes in Biomathematics (S. Levin, ed.), Vol. 2, pp. 155-161. New York: Springer Verlag.
55. MICHELSON, S. & LEITH, J. T. 1993 Growth factors and growth control of heterogeneous cell populations. Bull. Math. Biol. 55, 993-1011.
56. MICHELSON, S. & SLATE, D. 1994 A mathematical model for the inhibition of the multidrug resistance associated p-glycogen pump. Bull. Math. Biol. 56, 207-223.
57. MITUS, A. J. & ROSENTHAL, D. S. 1991 Adult leukaemias. In: Clinical Oncology (A. I. Holleb et al., eds.), pp. 410-432. Atlanta, GA: American Cancer Society.
58. MORRISON, M. S. & VOIT, E. O. 1991 Effects of the Variability of Cell Cycle Duration on Labelling Experiments. Lecture Notes in Pure and Applied Mathematics, Vol. 131, pp. 593-608. New York: Springer Verlag.
59. NANI, F. K. & OǦUZTÖRELI, M. N. 1992 Modeling and simulation of liposomal drug delivery to the central nervous system. In: Biomedical Modelling and Simulation (J. Eisenfeld, D. S. Levine, & M. Witten, eds.), pp. 351-367. London: Elsevier Science.
60. NERI, A., KNOWLES, D. M., GRECO, A., MCCORMACK, F., & DALLA-FAVERA, R. 1988 Analysis of ras oncogene mutations in human lymphoid malignancies. Proc. Natl. Acad. Science USA 85, 9268-9272.
61. OǦUZTÖRELI, M. N. 1966 Time Lag Control Systems. New York: Academic Press.
62. OǦUZTÖRELI, M. N., TSOKOS, C. P. & AKABUTU, J. 1983 A kinetic study of chemotherapy. Applied Math. Comput. 12, 255-300.
63. OISHI, N. 1983 In: Concepts in Cancer Medicine (S. B. Kahn et al., eds.), pp. 597-618. London: Academic Press.
64. PALLAVICINI, M. G., GRAY, J. W., & FOLSTAD, L. J. 1982 Quantitative analysis of the cytokinetic response of KHT tumours in vivo to 1-β-D-Arabinosylcytosine. Cancer Res. 42, 3125-3131.
65. PERRY, M. C. (ed) 1992 The Chemotherapy Sourcebook, pp. 213-220. Baltimore, MD: Williams and Wilkins.
66. RITTGEN, W. & TAUTU, P. 1976 Branching Models for the Cell Cycle. Lecture Notes in Biomathematics (S. Levin, ed.), Vol. 11, pp. 109-126. New York: Springer Verlag.
67. SAATY, L. T. 1981 Delay differential equations. In: Modern Nonlinear Equations, pp. 213-261. New York: Dover Publications.
68. SCHIFFER, C. A. & SCHIMPFF, S. C. 1991 Acutre leukaemia. In: Comprehensive Textbook of Oncology, Vol. 2 (A.R. Moossa, S. G. Schimpff, & M. C. Robson, eds.), pp. 1203-1219. Philadelphia, PA: Williams & Wilkins.
69. SEE-LASLEY, K. & IGNOFFO, R. J. 1981 Manual of Oncologic Therapeutics, pp. 138-139. London: C.V. Mosby.
70. SHARGEL, L. & Yu, A. B. C. 1985 Applied Biopharmaceutical and Pharmacokinetics, Ch. 14 pp. 255-277. Norwalk, CT: Appleton-Century-Crofts.
71. SILVER, R. T., LAUPER, R. D. & JAROWSKI, C. I. 1987 A Synopsis of Cancer Chemotherapy. New York: Yorke Medical Books.
72. SKEEL, R. T. 1984 The biologic and pharmacologic basis of cancer chemotherapy. In: Manual of Cancer Chemotherapy (R.T. Skeel, ed.), pp. 3-12. Boston: Little Brown.
73. SKIPPER, H. E. 1969 Improvement of the model systems, Cancer Res. 29, 2329-2333.
74. SKIPPER, H. E. & ZUBROD, C. G. 1968 Some thoughts concerning cancer and cancer therapy. Med. Tribune Med. News. 9, 11-16.
75. SWAN, G. W. 1987a Tumour growth models and cancer chemotherapy. In: Cancer Modelling (J. R. Thompson & B. W. Brown, eds.), pp. 91-180. New York: Marcel Dekker.
76. SWAN, G. W. 1987b Optimal control applications in the chemotherapy of multiple myeloma. IMA J. Math. Appl. Med. Biol. 4, 139-160.
77. SWAN, G. W. 1988 General application of optimal control theory in cancer chemotherapy. IMA J. Math. Appl. Med. Biol. 5, 303-316.
78. SWAN, G. W. 1990. Role of optimal control theory in cancer chemotherapy. Math. Biosci. 101, 237-284.
79. gG multiple myeloma. Bull. Math. Biol. 39, 317-333.
80. TAKAHASHI, M. 1966 Theoretical basis for cell cycle analysis I. J. Theor. Biol. 13, 202-211.
81. TAN, W. Y. & BROWN, C. C. 1989 Cancer chemotherapy with immunostimulation: A non-homogeneous stochastic model for drug resistance 1. One drug case. Math. Biosci. 97, 145-160.
82. TANNOCK, I. 1978 Cell kinetics and chemotherapy: A critical review. Cancer Treat. Rep. 62, 1117.
83. TANNOCK, I. 1980 Cell kinetics - Where to now? Cell Tissue Kin. 13, 571-573.
84. TYSON, J. J. & DICKMANN, O. 1986 Sloppy size control of the cell division cycle. J. Theor. Biol. 118, 405-426.
85. TYSON, J. J. & HANNSGEN, K. B. 1985 The distribution of cell size and generation time in a model of the cell cycle incorporating size control and random transitions. J. Theor. Biol. 113, 29-62.
86. TYSON, J. J. & HANNSGEN, K. B. 1986 Cell growth and division: Global asymptotic stability of the size distribution in probabilistic models of the cell cycle. J. Math. Biol. 23, 231-246.
87. USHER, J. R. 1994 Some mathematical models for cancer chemotherapy. Comput. Math. Applic. 28, 73-80.
88. USHER, J. R. & HENDERSON, D. 1996 Some drug-resistant models for chemotherapy. Part 1: Cycle-nonspecific drugs. IMA J. Math. Appl. Med. Biol. 13, 99-126.
89. VALERIOTE, F. A. 1975 Cell kinetics and tumour therapy: An overview. In: The Cell Cycle in Malignancy and Immunity (J. C Hampton, ed.), pp. 387-427. Technical Information Centre Office of Public Affairs. US Energy Research.
90. VALERIOTE, F. A. & EDELSTEIN, M. B. 1977 The role of cell kinetics in cancer chemotherapy. Semi. Oncol. 4, 217.
91. VAN DILLA, M. A. et al. 1969 Cell microfluorometry: A method for rapid fluorescence measurement. Science 163, 1213.
92. VAN PUTTEN, L. M. 1979 Cell kinetics, a guide for chemotherapy? In: Controversies in Cancer (H. J. Tagnon & M. J. Staquet, eds.), pp. 117-130. New York: Masson.
93. VAN PUTTEN, L. M. 1980 Growth delay and tumour relapse after adjuvant chemotherapy, the validity of models. Eur. J. Cancer 16, 173-176.
94. VAN PUTTEN, L. M. & EDELSTEIN, M. B. 1983 Animal models for drug scheduling. In: Cancer Chemotherapy 1 (F. M. Muggia, ed.), pp. 31-46. London: Martinus Nijhoff.
95. WAGNER, J. P. 1973 Properties of the Michaelis-Menten equation and its integrated form which are useful in Pharmacokinetics. J. Pharm. Biopharm. 1, 103-120.
96. WAGNER, J. P. 1975 Nonlinear pharmacokinetics. In: Fundamentals of Clinical Pharmacokinetics, pp. 247-284. Drug Intelligence Publications.
97. WEBB, G. F. 1985 Theory of Non-Linear Age-Dependent Population Dynamics. New York: Marcel Dekker.
98. WEBB, G. F. 1986 A model of proliferating cell populations with inherited cycle length. J. Math. Biol. 23, 269-282.
99. WEBB, G. F. 1987 Random transitions, size control and inheritance in cell population dynamics. Math. Biosci. 85, 71-91.
100. WHELDON, T. 1988 Mathematical Models in Cancer Research. Bristol: Elsevier Science.
101. WILKINSON, P. M. 1978 Clinical pharmacology of Adriamycin. In: Clinical Pharmacology of Adriamycin (H. M. Pinedo, ed.), pp. 209-223.
102. WILKINSON, P. M., MORICE, E. R., & LUCAS, S. B. 1978 Clinical and kinetic parameters that influence the response and toxicity of Methotrexate. In: Clinical Pharmacology of Antineoplastic Drugs (H. M. Pinido, ed.), pp. 29-38. Oxford: Elsevier/North-Holland Press.
103. Woo, K. B. & WIIG, K. M. 1973 Quantifying the progress of a tumour by bio-marker kinetics. In: The Cell Cycle in Malignancy and Immunity: Proceedings of the Thirteen Annual Hanford Biology Symposium at Richland, Washington, 1-3 October 1973. Technical Information Centre, US Energy Research.
104. WOO, K. B., FUNKHOUSER, W. K., SULLIVAN, C., & ALABASTER, O. 1980 Analysis of the proliferation kinetics of Burkitts lymphoma cells. Cell Tissue Kin. 13, 591-604.
105. WORKMAN, P., BELPOMME, D. & ROBERT, J. 1993 New drug design and development in cancer: Present status and future perspectives. Cancer Chemother. Pharmacol. 32, 83-84.
106. YACOBI, A. & HALPERIN-WALEGA, E. 1988 Oral (Gastrointestinal) Sustained Release Formulations Design and Evaluation, pp. 1-160. Oxford: Pergamon Press.
107. ZIETZ, S. & NICOLINI, C. 1978 Deterministic mathematical models to obtain optimized drug metabolism and cell kinetic parameters as functions of dosage. In: Biomathematics and Cell Kinetics, pp. 431-438 (A. J. Valleron & P. D. Macdonald, eds.). Elsevier/North Holland.
108. ZIETZ, S., DESAIVE, C., GRATTAROLA, M., & NICOLINI, C. 1980 Modeling to determine dose dependence of drug and cell kinetic parameters. Comput. Biomed. Res. 13, 297-305.